Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2012 Sep 3:12:298.
doi: 10.1186/1472-6963-12-298.

Efficacy of a systematic depression management program in high utilizers of primary care: a randomized trial

Affiliations
Randomized Controlled Trial

Efficacy of a systematic depression management program in high utilizers of primary care: a randomized trial

Anne Berghöfer et al. BMC Health Serv Res. .

Abstract

Background: Approximately 25% of so-called high utilizers of medical care are estimated to suffer from depression. A large proportion of these individuals remain undiagnosed and untreated. This study aims to examine the effects of a systematic screening and collaborative treatment program on depression severity in small primary care practices of the German outpatient health care system.

Method: High utilizers of primary care who screened positive for depressive symptoms on the Brief Psychiatric Health Questionnaire (B-PHQ) were further diagnosed using the DIA-X, a standardized diagnostic interview, performed by trained and supervised interviewers. Patients with major depression were randomized (cluster randomization by practice) to (a) a six-month treatment program of pharmacotherapy, standardized patient and provider education, and physician and patient counseling or (b) six months of usual medical care. All subjects were followed for a 12-month observation period using the 17-item Hamilton Depression Rating scale (HAMD-17) rated by the treating physicians and the B-PHQ-9 rated by the patients.

Results: A total of 63 high utilizer patients were included in the trial (17 male, 46 female), 19 randomized to intervention, 44 to usual care. The mean age was 49.7 (SD 13.8). Most patients had one or more somatic co-morbidities. There was no significant difference in response (defined as a decrease in the HAMD-17 sum score of at least 50%) after six months of treatment (50% vs. 42%, p = 0.961, all analyses adjusted for age) and after 12 months of treatment (83% vs. 54%, p = 0.282) between groups. Using patient self-rating assessments with the B-PHQ-9 questionnaire the intervention was superior to treatment as usual at six months (83% vs. 16%, p = 0.000).There was no significant difference in HAMD-17 depression severity at six months between the groups (10.5 (SD 7.6) vs. 12.3 (SD 7.8), p = 0.718), but a trend at 12 months (4.7 (SD 8.0) vs. 11.2 (SD 7.4), p = 0.083). Again, using B-PHQ-9 sum scores depression severity was significantly lower in the intervention group than in the treatment as usual group after six months (6.4 (SD 5.2) vs. 11.5 (SD 5.8), p = 0.020), but not at 12 months (7.9 (SD 8.7) vs. 9.0 (SD 5.2), p = 0.858).

Conclusion: A systematic collaborating treatment program for depression in high utilizers in primary care showed superiority to treatment as usual only in terms of patients' self-assessment but not according to physicians' assessment. The advance of the intervention group at 6 months was lost after 12 months of follow-up. Overall, positive results from similar trials in the US health care systems could not be confirmed in a German primary care setting.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Study design of screening and randomized treatment of patients with depression in primary care (B-PHQ = Brief Patient Health Questionnaire, DIA-X = Diagnostic Expert System for Psychiatric Disorders, HAMD = Hamilton Depression Scale, CGI = Clinical Global Impression Scale, CGI-CS = Clinical Global Impression Change Score, SER = Sertralin, DOX = Doxepine).

Similar articles

Cited by

References

    1. Lopez AD, Mathers CD, Ezzati M, Jamison DT, Murray CJL. Global and regional burden of disease and risk factors, 2001: systematic analysis of population health data. Lancet. 2006;367:1747–1757. doi: 10.1016/S0140-6736(06)68770-9. - DOI - PubMed
    1. Bromet E, Andrade LH, Hwang I, Sampson NA, Alonso J, de Girolamo G, de Graaf R, Demyttenaere K, Hu C, Iwata N, Karam AN, Kaur J, Kostyuchenko S, Lépine JP, Levinson D, Matschinger H, Mora ME, Browne MO, Posada-Villa J, Viana MC, Williams DR, Kessler RC. Cross-national epidemiology of DSM-IV major depressive episode. BMC Medicine. 2011;9:90. doi: 10.1186/1741-7015-9-90. - DOI - PMC - PubMed
    1. Lépine JP, Gastpar M, Mendlewicz J. Tylee A, on behalf of the DEPRES Steering Committee. Int Clin Psychopharmacol. 1997;12:19–29. doi: 10.1097/00004850-199701000-00003. - DOI - PubMed
    1. The ESEMeD/MHEDEA 2000 Investigators. Prevalence of mental disorders in Europe: results from the European Study of the Epidemiology of Mental Disorders (ESEMeD) project. Acta Psychiatr Scand. 2004;109(suppl. 420):21–27. - PubMed
    1. Jacobi F, Wittchen HU, Hölting C, Höfler M, Pfister H, Müller N, Lieb R. Prevalence, co-morbidity and correlates of mental disorders in the general population: results from the German Health Interview and Examination Survey (GHS) Psychol Med. 2004;34:597–611. doi: 10.1017/S0033291703001399. - DOI - PubMed

Publication types

LinkOut - more resources